|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.01 CNY | +2.52% |
|
+1.61% | -14.25% |
| 07-10 | China Includes Two Mayinglong Pharmaceutical Products in Essential Medicines List | MT |
| 05-25 | Mayinglong Pharmaceutical Gets Regulatory Approval for Eye Drops | MT |
Company Valuation: Mayinglong Pharmaceutical Group Co., LTD.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 10,423 | 11,255 | 12,070 | 10,350 | - | - |
| Change | - | 7.98% | 7.24% | -14.25% | - | - |
| Enterprise Value (EV) | 10,423 | 11,255 | 12,070 | 10,350 | 10,350 | 10,350 |
| Change | - | 7.98% | 7.24% | -14.25% | 0% | 0% |
| P/E | - | 21.2x | 20.7x | 15.4x | 12.8x | 12.3x |
| PBR | - | 2.77x | 2.76x | 2.18x | 1.88x | 1.63x |
| PEG | - | - | 2.12x | 1x | 0.6x | 2.89x |
| Capitalization / Revenue | 3.32x | 3.02x | 3.12x | 2.4x | 2.18x | 2.01x |
| EV / Revenue | 0x | 0x | 0x | 2.4x | 2.18x | 2.01x |
| EV / EBITDA | - | 0x | 0x | 12.7x | 11.4x | 10.2x |
| EV / EBIT | - | 0x | 0x | 12.5x | 11.2x | 9.96x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | - | 1.23 | 1.35 | 1.56 | 1.88 | 1.96 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,137 | 3,728 | 3,867 | 4,318 | 4,754 | 5,142 |
| EBITDA 1 | - | 686.7 | 791.2 | 817 | 911 | 1,010 |
| EBIT 1 | - | 666.8 | 719.9 | 830 | 924 | 1,039 |
| Net income 1 | 443.3 | 528.1 | 581.5 | 674 | 745 | 843 |
| Net Debt | - | - | - | - | - | - |
| Reference price 2 | 24.18 | 26.11 | 28.00 | 24.01 | 24.01 | 24.01 |
| Nbr of stocks (in thousands) | 431,054 | 431,054 | 431,054 | 431,054 | - | - |
| Announcement Date | 4/12/24 | 4/2/25 | 4/24/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 15.01x | - | - | - | 1.49B | |
| 35.56x | 12.7x | 26.67x | 0.56% | 1,068B | |
| 28.51x | 6.52x | 18.04x | 2.02% | 641B | |
| 32.33x | 7.59x | 15.6x | 2.68% | 454B | |
| 19.49x | 4.75x | 11.79x | 2.78% | 351B | |
| 22.29x | 5.76x | 14.37x | 2.78% | 299B | |
| 21.47x | 4.5x | 12.72x | 1.93% | 266B | |
| 14.4x | 5.35x | 11.02x | 3.48% | 220B | |
| 24.71x | 6.49x | 11.44x | 2.68% | 203B | |
| -47.03x | 5.64x | 31.15x | 2.53% | 162B | |
| Average | 16.68x | 6.59x | 16.98x | 2.38% | 366.48B | |
| Weighted average by Cap. | 24.75x | 7.96x | 18.76x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 600993 Stock
- Valuation Mayinglong Pharmaceutical Group Co., LTD.
Select your edition
All financial news and data tailored to specific country editions
